FindTrial
Sign In

COVID-19 Global Rheumatology Alliance

Rheumatology COVID-19 registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/08/027165
Enrollment
3000
Registered
2020-08-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention1: NO INTERVENTION NO COMPARATOR It is an OBSERVATIONAL Study REGISTRY: NO INTERVENTION NO COMPARATOR It is an OBSERVATIONAL Study

Sponsors

Univesity of California Sanfrancisco
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Rheumatological autoimmune disease who develop COVID-19

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Protective role of HCQS Outcomes of COVID infection Protective or risk due to other medications Risk of bad outcomes due to underlying diagnosisTimepoint: baseline, 2 weeks, 4 weeks,—

Secondary

MeasureTime frame
Protective role of HCQS Protective or risk due to other medications Risk of bad outcomes due to underlying diagnosisTimepoint: 1 month,—

Countries

Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, Egypt, Finland, France, Germany, Iceland, India, Iran (Islamic Republic of), Italy, Mexico, New Zealand, Norway, Sweden, United Kingdom, United States of America

Contacts

Public ContactSharath Kumar

Columbia Asia Referral Hospital - Yeshwantpur

sharath.k@columbiaindiahospitals.com9663654655

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026